Comparative Pharmacology
Head-to-head clinical analysis: ANTIZOL versus SODIUM NITRITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTIZOL versus SODIUM NITRITE.
ANTIZOL vs SODIUM NITRITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antizol (fomepizole) is a competitive inhibitor of alcohol dehydrogenase, the enzyme that catalyzes the oxidation of ethanol to acetaldehyde. It also inhibits the metabolism of ethylene glycol and methanol to their toxic metabolites.
Sodium nitrite is a vasodilator that acts by relaxing vascular smooth muscle, primarily through the generation of nitric oxide (NO). It also converts hemoglobin to methemoglobin, which binds cyanide, thereby acting as an antidote for cyanide poisoning.
Initial: 15 mg/kg IV over 10 minutes, then 3 mg/kg IV every 4 hours for 2 doses, then 3 mg/kg IV every 6 hours for 4 doses.
300 mg (10 mL of a 30 mg/mL solution) intravenously over 2-4 minutes, followed immediately by sodium thiosulfate. May repeat once after 30-60 minutes if needed.
None Documented
None Documented
Terminal elimination half-life: 2.5-3.5 hours in adults. Clinical context: Dose adjustment recommended in severe renal impairment (CrCl <30 mL/min) due to prolonged half-life.
Terminal half-life: 0.5–1 hour (nitrite); due to rapid oxidation to nitrate, which has a half-life of 5–8 hours. Clinically, methemoglobin reduction requires monitoring for 2–4 hours.
Renal: 80-95% as parent drug and metabolites. Fecal: <5%. Biliary excretion is negligible.
Primarily renal; 60-70% as nitrate and unchanged nitrite; minor biliary (<5%) and fecal (<2%) elimination.
Category C
Category C
Antidote
Antidote